A Phase 3 interventional study of Somatropin in Endocrine System Diseases, sponsored by Pfizer. Terminated at 1 site in France. Open to participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2012-12-04.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.
322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.
This study's enrollment of 21 is below the median of 69 across 221 interventional studies indexed under Endocrine System Diseases.
Browse Endocrine System Diseases studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Somatropin
Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
Change From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Year 3
Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 3
Change From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Final Height
Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, final height (assessed up to Year 9.5)
Change From Baseline in Height Standard Deviation Score (SDS) at Year 3
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 3
Change From Baseline in Height Standard Deviation Score (SDS) at Final Height
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, final height (assessed up to Year 9.5)
Change From Baseline in Predicted Height Standard Deviation Score (SDS) at Year 3
Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 3
Change From Baseline in Predicted Height Standard Deviation Score (SDS) at Final Height
Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, final height (assessed up to Year 9.5)
Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGFBP3) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Change From Baseline in Lean Mass and Fat Mass at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9
Lean mass and fat mass: measurements of body composition assessed using Dual Energy X-ray Absorptiometry (DEXA) scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9
Change From Baseline in Bone Mineralization at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9
Bone mineralization, an estimate of the amount of mineral (such as calcium) in the bone, was assessed using DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9
Change From Baseline in Weight Standard Deviation Score (SDS) at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender- appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Change From Baseline in Corticosteroid Dose at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Participants included in previous study CTN 97-8129-016 were eligible for this study.
| Milestone | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Started | 11 | 10 |
| Completed | 6 | 4 |
| Not completed | 5 | 6 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Study terminated by sponsor | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 |
Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline | -0.21 (-3.0 to 4.5) | -2.96 (-6.4 to 1.5) |
| Change at Year 3 | 1.34 (-3.6 to 6.2) | 3.52 (-5.1 to 11.2) |
Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
No measurements were reported for this outcome.
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline | -0.61 (-3.7 to 1.4) | -2.34 (-4.8 to -1.4) |
| Change at Year 3 | 0.73 (-2.4 to 2.6) | 1.21 (-0.7 to 2.4) |
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline | 0.96 (-3.7 to 2.3) | -0.94 (-1.4 to -0.5) |
| Change at Final Height | -0.43 (-0.8 to 0.5) | 0.08 (-0.7 to 0.9) |
Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline | -0.76 (-1.8 to 0.7) | -2.43 (-2.6 to -1.6) |
| Change at Year 3 | 0.68 (-2.6 to 2.0) | 1.63 (0.1 to 2.3) |
Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline | -0.84 (-1.8 to 0.1) | -1.74 (-2.4 to -1.1) |
| Change at Final Height | -0.67 (-2.4 to 1.0) | 0.71 (0.1 to 1.3) |
| milligram per deciliter (mg/dL) | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline (n = 11, 10) | 0.0361 (0.0181 to 0.0868) | 0.0165 (0.0075 to 0.0517) |
| Change at Year 0.5 (n = 9, 10) | 0.0017 (-0.0256 to 0.0681) | 0.0255 (-0.0145 to 0.0390) |
| Change at Year 1 (n = 11, 10) | 0.0093 (-0.0358 to 0.0488) | 0.0329 (-0.0061 to 0.0531) |
| Change at Year 1.5 (n = 11, 9) | 0.0066 (-0.0194 to 0.0599) | 0.0406 (-0.0035 to 0.0754) |
| Change at Year 2 (n = 10, 9) | 0.0221 (-0.0292 to 0.0534) | 0.0223 (0.0055 to 0.0673) |
| Change at Year 2.5 (n = 8, 8) | 0.0201 (-0.0237 to 0.0470) | 0.0366 (-0.0109 to 0.0558) |
| Change at Year 3 (n = 7, 9) | 0.0130 (-0.0049 to 0.0648) | 0.0445 (-0.0060 to 0.0557) |
| Change at Year 3.5 (n = 7, 7) | 0.0100 (-0.0022 to 0.0436) | 0.0396 (0.0014 to 0.0707) |
| Change at Year 4 (n = 6, 7) | 0.0212 (-0.0014 to 0.0485) | 0.0453 (0.0175 to 0.0646) |
| Change at Year 4.5 (n = 5, 6) | 0.0142 (0.0042 to 0.0303) | 0.0431 (0.0080 to 0.1233) |
| Change at Year 5 (n = 5, 7) | 0.0236 (0.0164 to 0.0530) | 0.0369 (0.0258 to 0.0902) |
| Change at Year 5.5 (n = 4, 5) | 0.0186 (0.0119 to 0.0356) | 0.0448 (0.0258 to 0.0965) |
| Change at Year 6 (n = 4, 5) | 0.0256 (0.0000 to 0.0434) | 0.0454 (0.0155 to 0.0718) |
| Change at Year 6.5 (n = 2, 5) | 0.0195 (0.0125 to 0.0264) | 0.0593 (0.0512 to 0.0766) |
| Change at Year 7 (n = 1, 5) | 0.0254 (0.0254 to 0.0254) | 0.0424 (0.0393 to 0.0766) |
| Change at Year 7.5 (n = 0, 3) | NA (NA to NA) | 0.0529 (0.0527 to 0.0599) |
| Change at Year 8 (n = 0, 2) | NA (NA to NA) | 0.0576 (0.0468 to 0.0683) |
| Change at Year 8.5 (n = 0, 1) | NA (NA to NA) | 0.0280 (0.0280 to 0.0280) |
| Change at Year 9 (n = 2, 1) | 0.0363 (0.0159 to 0.0567) | 0.0403 (0.0403 to 0.0403) |
No measurements were reported for this outcome.
Lean mass and fat mass: measurements of body composition assessed using Dual Energy X-ray Absorptiometry (DEXA) scan.
No measurements were reported for this outcome.
Bone mineralization, an estimate of the amount of mineral (such as calcium) in the bone, was assessed using DEXA scan.
| grams | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline (n = 11, 10) | 643.00 (454.0 to 998.0) | 565.40 (136.0 to 1305.0) |
| Change at Year 1 (n = 11, 10) | 118.40 (-792.7 to 459.6) | 104.67 (9.0 to 340.0) |
| Change at Year 2 (n = 10, 9) | 231.30 (-47.5 to 774.4) | 272.70 (63.0 to 590.0) |
| Change at Year 3 (n = 7, 8) | 403.80 (25.0 to 862.5) | 375.27 (106.0 to 1084.9) |
| Change at Year 4 (n = 4, 3) | 903.20 (277.1 to 1448.1) | 518.70 (450.8 to 1047.9) |
| Change at Year 5 (n = 4, 7) | 938.30 (591.8 to 1787.6) | 829.00 (421.7 to 1245.8) |
| Change at Year 6 (n = 4, 5) | 998.05 (371.4 to 1984.2) | 818.40 (112.5 to 1105.5) |
| Change at Year 7 (n = 1, 5) | 1408.50 (1408.5 to 1408.5) | 1206.10 (739.6 to 1437.3) |
| Change at Year 8 (n = 0, 2) | NA (NA to NA) | 1376.05 (1351.7 to 1400.4) |
| Change at Year 9 (n = 2, 1) | 1210.15 (898.6 to 1521.7) | 1376.30 (1376.3 to 1376.3) |
Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender- appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline (n = 11, 10) | 0.04 (-5.4 to 5.0) | -2.06 (-4.0 to 2.6) |
| Change at Year 0.5 (n = 9, 10) | 0.06 (-0.8 to 1.2) | 0.25 (-0.7 to 0.4) |
| Change at Year 1 (n = 11, 10) | 0.25 (-1.1 to 0.9) | 0.31 (-0.1 to 1.5) |
| Change at Year 1.5 (n = 11, 9) | 0.34 (-1.6 to 2.3) | 0.62 (-0.3 to 2.3) |
| Change at Year 2 (n = 10, 9) | 0.46 (-1.1 to 2.2) | 1.23 (-0.2 to 2.7) |
| Change at Year 2.5 (n = 8, 8) | 0.77 (-1.1 to 2.6) | 1.51 (-0.9 to 3.2) |
| Change at Year 3 (n = 7, 9) | 0.61 (-1.2 to 2.7) | 1.48 (-1.9 to 3.7) |
| Change at Year 3.5 (n = 7, 7) | 0.78 (-1.3 to 3.0) | 1.56 (-1.9 to 3.7) |
| Change at Year 4 (n = 6, 7) | 0.58 (-1.0 to 2.4) | 1.96 (-2.3 to 3.8) |
| Change at Year 4.5 (n = 5, 6) | 1.46 (-0.4 to 2.7) | 1.78 (-2.7 to 4.1) |
| Change at Year 5 (n = 5, 7) | 2.06 (0.1 to 2.8) | 2.08 (-3.0 to 3.9) |
| Change at Year 5.5 (n = 3, 5) | 2.10 (1.7 to 2.6) | 3.25 (1.0 to 3.8) |
| Change at Year 6 (n = 3, 5) | 1.89 (1.8 to 2.2) | 2.95 (1.2 to 4.4) |
| Change at Year 6.5 (n = 2, 5) | 2.03 (1.9 to 2.2) | 3.30 (0.8 to 5.0) |
| Change at Year 7 (n = 1, 5) | 1.7 (1.7 to 1.7) | 2.91 (0.2 to 5.2) |
| Change at Year 7.5 (n = 0, 3) | NA (NA to NA) | 1.49 (0.3 to 3.1) |
| Change at Year 8 (n = 0, 2) | NA (NA to NA) | 1.06 (0.5 to 1.6) |
| Change at Year 8.5 (n = 0, 1) | NA (NA to NA) | 0.7 (0.7 to 0.7) |
| Change at Year 9 (n = 1, 1) | 2.0 (2.0 to 2.0) | 1.4 (1.4 to 1.4) |
| mg | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Baseline (n = 11, 10) | 7.50 (1.0 to 40.0) | 4.75 (2.0 to 13.5) |
| Change at Year 0.5 (n = 9, 10) | 0.00 (-11.0 to 0.0) | 0.00 (-2.5 to 4.8) |
| Change at Year 1 (n = 11, 9) | 0.00 (-15.0 to 20.3) | -0.67 (-8.5 to 36.0) |
| Change at Year 1.5 (n = 11, 8) | 0.00 (-17.0 to 7.5) | 0.50 (-5.0 to 8.8) |
| Change at Year 2 (n = 10, 8) | 0.00 (-19.0 to 10.6) | -0.50 (-6.3 to 11.9) |
| Change at Year 2.5 (n = 8, 7) | 0.04 (-28.0 to 7.5) | 1.83 (-7.8 to 11.9) |
| Change at Year 3 (n = 7, 7) | 0.00 (-34.2 to 1.0) | 1.75 (-9.5 to 19.4) |
| Change at Year 3.5 (n = 7, 6) | -0.75 (-36.0 to 2.9) | 1.83 (-10.3 to 12.5) |
| Change at Year 4 (n = 6, 7) | -1.88 (-4.5 to 0.0) | 0.25 (-10.0 to 9.7) |
| Change at Year 4.5 (n = 5, 6) | -3.40 (-10.0 to 0.0) | 0.23 (-9.0 to 215.4) |
| Change at Year 5 (n = 5, 7) | -3.50 (-10.0 to -0.6) | -2.00 (-9.5 to 15.0) |
| Change at Year 5.5 (n = 4, 5) | -1.83 (-4.5 to 486.5) | 0.25 (-9.5 to 18.3) |
| Change at Year 6 (n = 4, 5) | -1.83 (-5.5 to 9.0) | -1.00 (-11.0 to 10.6) |
| Change at Year 6.5 (n = 2, 5) | -2.46 (-3.7 to -1.3) | -1.00 (-11.0 to 3.0) |
| Change at Year 7 (n = 1, 5) | -2.50 (-2.5 to -2.5) | -1.00 (-11.0 to 2.0) |
| Change at Year 7.5 (n = 0, 3) | NA (NA to NA) | -7.00 (-12.0 to 0.5) |
| Change at Year 8 (n = 0, 2) | NA (NA to NA) | -3.25 (-7.0 to 5.0) |
| Change at Year 8.5 (n = 0, 1) | NA (NA to NA) | 0.50 (0.5 to 0.5) |
| Change at Year 9 (n = 2, 1) | -3.00 (-3.5 to -2.5) | -7.00 (-7.0 to -7.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin (With Previous Somatropin Exposure) | — | 6/11 (54.5%) | 11/11 (100%) |
| Somatropin (Without Previous Somatropin Exposure) | — | 2/10 (20%) | 9/10 (90%) |
| Event | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Juvenile arthritisMusculoskeletal and connective tissue disorders | 2/11 | 0/10 |
| LymphadenitisBlood and lymphatic system disorders | 0/11 | 1/10 |
| PyrexiaGeneral disorders | 1/11 | 1/10 |
| Lung infectionInfections and infestations | 0/11 | 1/10 |
| SinusitisInfections and infestations | 0/11 | 1/10 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/11 | 1/10 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/11 | 1/10 |
| HeadacheNervous system disorders | 0/11 | 1/10 |
| Nephrotic syndromeRenal and urinary disorders | 0/11 | 1/10 |
| Renal failure acuteRenal and urinary disorders | 0/11 | 1/10 |
| Event | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) |
|---|---|---|
| Insulin-like growth factor increasedInvestigations | 8/11 | 6/10 |
| Insulin resistanceMetabolism and nutrition disorders | 6/11 | 5/10 |
| Glucose tolerance impairedMetabolism and nutrition disorders | 5/11 | 0/10 |
| Juvenile arthritisMusculoskeletal and connective tissue disorders | 4/11 | 4/10 |
| BronchitisInfections and infestations | 1/11 | 3/10 |
| GastritisGastrointestinal disorders | 0/11 | 2/10 |
| FatigueGeneral disorders | 0/11 | 2/10 |
| Ear infectionInfections and infestations | 1/11 | 2/10 |
| Herpes zosterInfections and infestations | 0/11 | 2/10 |
| Nail candidaInfections and infestations | 0/11 | 2/10 |
| Age Continuous(years) | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) | Total |
|---|---|---|---|
| Mean | 8.3 ± 2.6 | 8.5 ± 3.3 | 8.4 ± 2.9 |
| Sex: Female, Male(Participants) | Somatropin (With Previous Somatropin Exposure) | Somatropin (Without Previous Somatropin Exposure) | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 5 | 6 | 11 |
The record gives a start of Mar 2002, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone